Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II –IIIA (N1–N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study
For patients with stage II –IIIA non-small-cell lung cancer (NSCLC), the current standard-of-care modality is surgery followed by adjuvant cisplatin-based chemotherapy [1,2]. However, the 5-year survival rate is only 19 %–46 % [3], and high toxicity and low compliance with this combined modality approach makes its benefit -risk ratio more unfavorable. To address this unmet medical need, the ADJUVANT study was conducted to test whether the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib, compared with vinorelbine plus cisplatin (VP) would be a preferable choice of adjuvant therapy for the EGFR-mutant subgroup of stage II–IIIA (N1–N2) NSCLC patients.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Jian Zeng, Wei-Min Mao, Qi-Xun Chen, Tao-Bo Luo, Yi-Long Wu, Qing Zhou, Xue-Ning Yang, Hong-Hong Yan, Wen-Zhao Zhong, Qun Wang, Song-Tao Xu, Lin Wu, Yi Shen, Yong-Yu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Ke Fei, Xiao-Fei Li, Jian Li, Cheng Huang, Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology